Efficient antitumor effects of a novel oncolytic adenovirus fully composed of species B adenovirus serotype 35.
CAR
CD46
adenovirus serotype 35
neutralizing antibody
oncolytic virus
Journal
Molecular therapy oncolytics
ISSN: 2372-7705
Titre abrégé: Mol Ther Oncolytics
Pays: United States
ID NLM: 101666776
Informations de publication
Date de publication:
26 Mar 2021
26 Mar 2021
Historique:
received:
18
01
2020
accepted:
18
01
2021
entrez:
22
2
2021
pubmed:
23
2
2021
medline:
23
2
2021
Statut:
epublish
Résumé
Oncolytic adenoviruses (OAds) are among the most promising oncolytic viruses. Almost all oncolytic adenoviruses are composed of human adenovirus serotype 5 (Ad5) (OAd5). However, expression of the primary infection receptor for Ad5, coxsackievirus-adenovirus receptor (CAR), often declines on malignant tumor cells, resulting in inefficient infection in CAR-negative tumor cells. In addition, at least 80% of adults have neutralizing antibodies against Ad5. In this study, we developed a novel OAd fully composed of OAd35. OAd35 recognizes CD46, which is ubiquitously expressed on almost all human cells and is often upregulated on malignant tumor cells, as an infection receptor. Moreover, 20% or fewer adults have neutralizing antibodies against Ad35. OAd35 mediated efficient cell lysis activities at levels similar to OAd5 in CAR-positive tumor cells, while OAd35 showed higher levels of cell lysis activities than OAd5 in CAR-negative tumor cells. Anti-Ad5 serum significantly inhibited
Identifiants
pubmed: 33614920
doi: 10.1016/j.omto.2021.01.015
pii: S2372-7705(21)00016-4
pmc: PMC7878985
doi:
Types de publication
Journal Article
Langues
eng
Pagination
399-409Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
F.S. and H.M. have the potential to receive patent royalities from Oncolys BioPharm, Inc. The other authors declare no conflicts of interest.
Références
J Virol. 2007 May;81(9):4654-63
pubmed: 17329340
Virology. 2003 Jul 5;311(2):384-93
pubmed: 12842627
Gene Ther. 2005 Oct;12(19):1424-33
pubmed: 15944730
Mol Med Rep. 2016 Sep;14(3):2541-7
pubmed: 27485384
Hum Gene Ther. 1998 Nov 20;9(17):2577-83
pubmed: 9853524
Oncol Rep. 2005 Oct;14(4):831-5
pubmed: 16142339
Int J Cancer. 2013 Sep 15;133(6):1479-88
pubmed: 23444104
Nat Med. 2000 Oct;6(10):1134-9
pubmed: 11017145
Exp Hematol. 2006 Jun;34(6):713-20
pubmed: 16728275
Mol Ther Oncolytics. 2019 Nov 02;15:234-247
pubmed: 31872046
Oncolytic Virother. 2018 May 03;7:43-51
pubmed: 29765912
Cancer Gene Ther. 2007 Feb;14(2):211-9
pubmed: 17082793
Nat Rev Drug Discov. 2019 Sep;18(9):689-706
pubmed: 31292532
J Virol. 2016 Jun 10;90(13):5915-27
pubmed: 27076643
J Virol. 2009 Mar;83(5):2130-9
pubmed: 19073718
Int J Cancer. 2005 Feb 20;113(5):738-45
pubmed: 15499626
Annu Rev Immunol. 1991;9:431-55
pubmed: 1910685
J Virol. 2012 Jan;86(1):625-9
pubmed: 22072776
Gene Ther. 2004 Dec;11(23):1694-702
pubmed: 15496964
Cancer Res. 2004 Jul 15;64(14):4919-26
pubmed: 15256464
J Virol. 2003 Aug;77(15):8263-71
pubmed: 12857895
J Clin Invest. 1989 Aug;84(2):538-45
pubmed: 2474570
Virology. 1968 Sep;36(1):115-25
pubmed: 5669982
Nat Med. 2003 Nov;9(11):1408-12
pubmed: 14566335
Gene Ther. 2003 Jun;10(12):1041-8
pubmed: 12776162
Mol Ther. 2003 Nov;8(5):813-21
pubmed: 14599815
Anticancer Res. 2012 Apr;32(4):1145-52
pubmed: 22493343
Gene Ther. 2007 Jun;14(11):912-9
pubmed: 17377598
Virology. 1996 Jun 1;220(1):152-62
pubmed: 8659107
J Virol. 1996 Apr;70(4):2296-306
pubmed: 8642656
Vaccine. 2011 Jul 18;29(32):5203-9
pubmed: 21619905
Int J Cancer. 2004 Jul 1;110(4):475-80
pubmed: 15122578
Nature. 2006 May 11;441(7090):239-43
pubmed: 16625206
Hum Gene Ther. 2009 Apr;20(4):361-73
pubmed: 19199789
Mol Ther. 2012 Feb;20(2):306-16
pubmed: 22086234
Mol Ther. 2008 Oct;16(10):1665-73
pubmed: 18665155
Clin Cancer Res. 2004 Nov 1;10(21):7199-206
pubmed: 15534093
Cancer Res. 2002 Jul 1;62(13):3812-8
pubmed: 12097294
Mol Cancer Res. 2007 Aug;5(8):823-32
pubmed: 17699108
Anticancer Res. 2007 Jul-Aug;27(4B):2311-6
pubmed: 17695519
Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15408-13
pubmed: 26607445
Clin Cancer Res. 2001 Jan;7(1):120-6
pubmed: 11205899
J Immunol. 2005 Jun 1;174(11):7179-85
pubmed: 15905562
J Immunol. 1990 Jul 1;145(1):238-45
pubmed: 1694203
Science. 2015 Oct 30;350(6260):568-71
pubmed: 26405230
Hum Gene Ther. 2000 Jul 20;11(11):1553-67
pubmed: 10945769
Mol Immunol. 2003 Sep;40(2-4):109-23
pubmed: 12914817
J Virol. 2009 Jan;83(1):479-83
pubmed: 18945780
Cancer Gene Ther. 2011 Apr;18(4):288-96
pubmed: 21183947
Br J Cancer. 1985 Mar;51(3):419-23
pubmed: 3970818
Virology. 2009 Nov 25;394(2):311-20
pubmed: 19765790
PLoS One. 2012;7(8):e41936
pubmed: 22870265
Vaccine. 2011 May 17;29(22):3837-41
pubmed: 21447314
Rev Med Virol. 2009 May;19(3):165-78
pubmed: 19367611
J Virol. 2005 Nov;79(22):14429-36
pubmed: 16254377